Current treatments for Alzheimer's disease: Cholinesterase inhibitors

Journal of Clinical Psychiatry

Volumn 64, Issue SUPPL. 9, 2003, Pages 11-17

  Doody, Rachelle S ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLINESTERASE INHIBITOR; DONEPEZIL; GALANTAMINE; PLACEBO; RIVASTIGMINE;

ALZHEIMER DISEASE; BEHAVIOR; CLINICAL TRIAL; COGNITION; DEMENTIA; DIARRHEA; DISEASE COURSE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; GASTROINTESTINAL SYMPTOM; HUMAN; NAUSEA; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; SIDE EFFECT; WEIGHT REDUCTION;

ALZHEIMER DISEASE; BEHAVIORAL SYMPTOMS; CARBAMATES; CHOLINESTERASE INHIBITORS; CLINICAL TRIALS; COGNITION DISORDERS; GALANTAMINE; HUMANS; INDANS; MULTICENTER STUDIES; PHENYLCARBAMATES; PIPERIDINES; TREATMENT OUTCOME;

EID: 0041921105     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (24)

1. Stahl SM. Essential Psychopharmacology. 2nd ed. New York, NY: Cambridge University Press; 2000
2. Nordberg A, Svensson AL. Cholinesterase inhibitors in the treatment of Alzheimer's disease: a comparison of tolerability and pharmacology. Drug Saf 1998;19:465-480
3. Doody RS, Stevens JC, Beck C, et al. Practice parameters management of dementia (an evidence-based review). Neurology 2001;56:1154-1166
4. Corey-Bloom J, Anand R, Veach J. A randomized trial evaluating the efficacy and safety of ENA 713 (rivastigmine tartrate), a new acetylcholinesterase inhibitor, in patients with mild to moderately severe Alzheimer's disease. Int J Geriatr Psychopharmacol 1998;1:55-65
5. Raskind MA, Peskind ER, Wessel T, et al. Galantamine in AD: a 6-month randomized, placebo-controlled, trial with a 6-month extension. Neurology 2000;54:2261-2268
6. Rogers SL, Farlow MR, Doody RS, et al. A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease. The Donepezil Study Group. Neurology 1998;50:136-145
7. Feldman H, Gauthier S, Hecker J, et al. A 24-week, randomized, double-blind study of donepezil in moderate to severe Alzheimer's disease. Neurology 2001;57:613-620
8. Mohs RC, Doody RS, Morris JC, et al. A 1-year, placebo-controlled preservation of function survival study of donepezil in AD patients. Neurology 2001;57:481-488
9. Winblad B. Maintaining functional and behavioral abilities in Alzheimer's disease. Alzheimer Dis Assoc Disord 2001;15(suppl 1):S34-S40
10. Tariot PN, Solomon PR, Morris JC, et al. A 5-month, randomized, placebo-controlled trial of galantamine in Alzheimer's disease. The Galantamine USA-10 Study Group. Neurology 2000;27:2269-2276
11. McKeith IG, Burn DJ, Ballard CG, et al. Dementia with Lewy bodies. Semin Clin Neuropsychiatry 2003;8:46-57
12. Torfs K, Feldman H. 12-Month decline in cognitive and daily function in patients with mild-to-moderate Alzheimer's disease: two randomized, placebo-controlled studies. Presented at World Alzheimer's Congress; July 9-13, 2000; Washington, DC
13. Winblad B, Engedal K, Soininen H, et al. A 1-year, randomized, placebo-controlled study of donepezil in patients with mild to moderate AD. Neurology 2001;57:489-495
14. Rogers SL, Doody RS, Mohs RC, et al. Donepezil improves cognition and global function in Alzeheimer's disease: a 15-week, double-blind, placebo-controlled study. Arch Intern Med 1998;158:1021-1031
15. Doody RS, Geldmacher DS, Gordon B, et al. Open-label, multicenter, phase 3 extension study of the safety and efficacy of donepezil in patients with Alzheimer's disease. Arch Neurol 2001;58:427-433
16. Farlow MR, Anand R, Messina J Jr, et al. A 52-week study of the efficacy of rivastigmine in patients with mild to moderately severe Alzheimer's disease. Eur Neurol 2000;44:236-241
17. Doody RS, Trvyen L, Hammond G. The efficacy of galantamine is maintained for at least 2 years. Presented at First Congress of the European Union Geriatric Medical Society; Aug 29-Sept 1, 2001; Paris, France
18. Pratt RD, Perdomo CA. Donepezil-treated patients with probable vascular dementia demonstrate cognitive benefits. Ann N Y Acad Sci 2002;977: 513-522
19. Erkinjuntti T, Kurz A, Gauthier S, et al. Efficacy of galantamine in probable vascular dementia and Alzheimer's disease combined with cerebrovascular disease: a randomised trial. Lancet 2002;59:1283-1290
20. Ruberg M, Villageois A, Bonnet AM, et al. Acetylcholinesterase. J Neurol Psychiatry 1987;50:538-543
21. Mori S. Responses to donepezil in Alzheimer's disease and Parkinson's disease. Ann N Y Acad Sci 2002;977:493-500
22. Bymaster FP, Felder CC. Role of the cholinergic muscarinic system in bipolar disorder and related mechanisms of action of antipsychotic agents. Mol Psychiatry 2002;7(suppl 1):S57-S63
23. Stryjer R, Strous RD, Bar F, et al. Beneficial effect of donepezil augmentation for the management of comorbid schizophrenia and dementia. Clin Neuropharmacol 2003;26:12-17
24. Sahin HA, Gurvit IH, Bilgic B, et al. Therapeutic effects of an acetylcholinesterase inhibitor (donepezil) on memory in Wernicke-Korsakoff's disease. Clin Neuropharmacol 2002;25:16-20